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A critical role for the self-
assembly of Amyloid-β1-42 in 
neurodegeneration
Karen E. Marshall1, Devkee M. Vadukul1, Liza Dahal1,†, Alina Theisen1,‡, Milena W. Fowler1, 
Youssra Al-Hilaly1,2, Lenzie Ford1,$,&, György Kemenes1, Iain J. Day1, Kevin Staras1 & 
Louise C. Serpell1
Amyloid β1-42 (Aβ1-42) plays a central role in Alzheimer’s disease. The link between structure, 
assembly and neuronal toxicity of this peptide is of major current interest but still poorly defined. 
Here, we explored this relationship by rationally designing a variant form of Aβ1-42 (vAβ1-42) differing 
in only two amino acids. Unlike Aβ1-42, we found that the variant does not self-assemble, nor is it 
toxic to neuronal cells. Moreover, while Aβ1-42 oligomers impact on synaptic function, vAβ1-42 does 
not. In a living animal model system we demonstrate that only Aβ1-42 leads to memory deficits. Our 
findings underline a key role for peptide sequence in the ability to assemble and form toxic structures. 
Furthermore, our non-toxic variant satisfies an unmet demand for a closely related control peptide for 
Aβ1-42 cellular studies of disease pathology, offering a new opportunity to decipher the mechanisms 
that accompany Aβ1-42-induced toxicity leading to neurodegeneration.
Alzheimer’s disease (AD) is characterised by the deposition of Aβ as amyloid fibrils in extracellular plaques, and 
the intracellular accumulation of tau as neurofibrillary tangles in the brain. Mutations in Aβ and the amyloid 
precursor protein (APP) are linked to familial AD; hence Aβ is thought to play an important role in the disease 
process1,2. Numerous studies have been carried out to try to better understand how Aβ contributes to the neu-
rodegeneration observed in AD patients and the symptoms of the disease. Self-assembled Aβ has been shown to 
cause membrane defects3,4, disruption to neuronal networks5,6, neuronal dysfunction7–9, impairment of long-term 
potentiation10, and changes in animal behavior7,11,12. Based on these reports, the current consensus is that Aβ con-
version and self-assembly into oligomeric forms is responsible for neuronal death in AD, although the exact role 
of fibrillar amyloid forms of Aβ and the specific mechanisms of toxicity are still very much debated.
The Aβ peptide is a member of a large group of amyloidogenic peptides and proteins13 whose toxic properties 
are believed to be specifically linked to their amyloidogenicity14. However, a detailed mechanistic understanding 
of how Aβ misfolding leads to neuronal dysfunction and eventual death remains limited. One critical constraint 
has been the lack of a suitable peptide against which the toxic properties of Aβ can be rigorously assessed. At 
present, most researchers typically use a buffer or alternative vehicle solution, but neither takes account of the 
structural features of Aβ oligomers or other aggregated isoforms that may be responsible for neurotoxic actions. 
Although scrambled, reversed or rodent Aβ1-42 sequences are occasionally used as controls, the assembly, struc-
ture and toxicity of these peptides have never been characterized in detail. Therefore a non-assembling pep-
tide is not available to compare the effects with Aβ1-42. In practise, a peptide with an essentially identical size 
and sequence to Aβ is required, but which neither assembles nor causes cell death. The importance of using 
assembly-incompetent peptides cannot be understated if robust conclusions are to be drawn on how self-assembly 
and amyloidogenesis contributes to disease. A second issue that has hampered progress in delineating Aβ action, 
is the propensity of the peptide to self-assemble: a process that is difficult to control since it is influenced by many 
factors such as peptide concentration, solvent type, temperature and the presence of seeds that can accelerate 
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assembly15,16. As a result, preparation procedures are liable to substantial variability in the type and size of aggre-
gates formed16,17 which confounds simple interpretation of findings into what species contribute to cell death. 
Importantly, although monomeric Aβ has not been implicated as playing a role in toxic effects, it has not been 
previously possible to ensure the preparation of pure monomeric Aβ, and that it remains so for extended periods. 
For the first time, we have rationally designed and extensively characterized a non-oligomeric peptide, represent-
ing a major breakthough in the ability to dissect which structural species are responsible for Alzheimer’s deficits.
Here, we report an approach that addresses two major limitations to AD research; the lack of a non-assembling 
peptide to compare to, and the need for a preparation method that produces consistent oligomer populations, 
and provides the basis for tightly-controlled studies of Aβ action. Specifically, we outline the rational design and 
generation of a non-aggregation prone variant of Aβ, identical to the wild type 1–42 sequence with the exception 
of two amino acid substitutions. We show that in combination with a protocol designed to remove pre-aggregates 
and potentially contaminating solvents3,17 we can produce highly consistent peptide preparations of Aβ1-42 and 
compare it to vAβ1-42 prepared under identical conditions. To gain insights into how the amyloidogenicity of 
Aβ1-42 impacts on its effects, we carried out a full structural and functional characterisation of both peptides. 
Compared to wild-type Aβ, we show that vAβ1-42 is compromised in its ability to aggregate and thus rendered 
non-toxic. Even over extended periods (7 days), we find that the variant peptide does not assemble into oligomers 
or fibres or develop any characteristic β-sheet structure. Furthermore, unlike Aβ1-42 oligomers, vAβ1-42 is not 
detected associated with or internalised into primary hippocampal neurons and has no effect on the metabolic 
activity or viability of neuroblastoma cells or neurons. Using optical imaging approaches we show that presyn-
aptic viability and vesicle recycling is compromised in Aβ treated but not vAβ-treated neurons. Using a whole 
animal model system, which is routinely employed for studying behavioural learning18, we show that normal 
memory formation occurs in vAβ1-42 but not Aβ-treated animals. This peptide illustrates the key role of amino 
acid sequence in the ability of Aβ1-42 to assemble and form toxic structures. Furthermore it can act as a robust 
control, providing an indispensible tool for studies on Aβ in AD.
Results and Discussion
Rational design of a non-assembling variant of the Aβ1-42 peptide. WALTZ algorithm19 was used 
to predict the effects of amino acid substitutions on the propensity of wildtype (WT) Aβ1-42 to form amyloid. 
WALTZ identifies two regions of WT Aβ1-42, between 15–22 and 36–42 that have the most amyloid-forming 
potential (Fig. 1). All possible amino acid substitutions were introduced into these regions and examined for 
amyloidogenicity using WALTZ19. The results were ranked and those substitutions that result in abolition of 
amyloidogenicity peaks were examined further. Substituting phenylalanine at position 19 (F19) with serine (S) 
and glycine at position 37 (G37) with aspartic acid (D) results in removal of the amyloidogenic regions in the 
Aβ1-42 peptide (Fig. 1). Previous studies have shown that phenylalanine and F19 in particular in Aβ plays an 
important role in driving assembly20–22 and solid state NMR measurements of Aβ specifically show molecular con-
tacts between F19 and L3423,24. Single substitutions of F19 have shown a significant reduction in Aβ assembly21,22. 
Substitution of F19 for leucine revealed that the F19 residue plays an important role in nucleation25. Glycine 
zippers have also been implicated in the amyloidogenic process and oligomer toxicity26. Aβ1-42 with G37L sub-
stitution dramatically reduced the toxic effects in cell culture and in vivo in Caenorhabditis elegans26. NMR studies 
have revealed that G37 fits into a solvent accessible turn together with G38 within oligomers24. Therefore, G37D 
was selected to disrupt this architecture. The substitution of hydrophobic F19 for smaller, polar serine and G37, 
for the negatively charged, bulky aspartic acid was predicted to disrupt the intermolecular contacts that drive and 
stabilise assembly into oligomers and fibrils.
F19S G37D substitutions impair assembly of Aβ1-42. Aβ1-42 F19S G37D, hereafter referred to as vAβ1-42, 
was characterised alongside WT Aβ1-42 using a range of biophysical techniques that report on the structural 
changes that take place during assembly. The peptides were prepared using a method that ensures removal 
Figure 1. The graph produced using WALTZ19 shows two peaks that indicate two amyloidogenic regions 
(residues 16–21 and residues 37–42) in Aβ1-42 compared to the trace for vAβ1-42 peptide design showing 
abolition of the amyloidogenic regions.
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of preformed aggregates and any potentially contaminating solvents as described in detail in the methods3,17. 
Peptide concentration was measured immediately after preparation and then the solution diluted to 50 μM to 
ensure reproducibility between experiments. We followed the assembly of both peptides over the course of one 
week using transmission electron microscopy (TEM) as well as spectroscopic and immunological methods to 
fully examine their assembly properties.
The morphology of the structures was visualised over time using TEM (Fig. 2a). Even at very early time points 
small spherical assemblies could be observed in the Aβ1-42 sample (Fig. 2a), consistent with previous reports3,27 
whilst the vAβ1-42 sample was free from any aggregates. After 2 hours, very small worm-like structures appear 
in Aβ1-42, which resemble protofibrils (Fig. 2a). After 24 hours long fibrils form and are present in abundance by 
72 hours. These are similar to those shown in recent studies27–29. Conversely, vAβ1-42 does not form fibrils, even 
up to one week after preparation.
To further investigate if vAβ1-42 was undergoing any structural reorganisation that could not be detected 
using TEM, temporal changes in the secondary structure of the peptide were monitored using circular dichroism 
(CD) (Fig. 2b). CD spectra confirm that Aβ1-42 is initially random coil for two to four hours (minima at 200 nm) 
and converts to β-sheet conformation (maximum at 195 nm and minimum at 218 nm). After 24 hours a clear 
β-sheet signal is apparent that becomes stronger at 48 hours, concomitant with the appearance of fibres by TEM. 
vAβ1-42 remains in a random coil conformation for the duration of the experiment (7 days). This confirms that 
the vAβ1-42 peptide remains soluble and does not assemble into a β-sheet rich structure.
To examine the fibrillogenesis process, a Thioflavin T (ThT) fluorescence assay was carried out to monitor 
amyloid assembly with time (Fig. 2c). Aβ1-42 shows some fluorescence intensity even at early time points, indi-
cating the presence of small species able to bind the dye. However this signal significantly increases at 24 hours, 
when fibres are visible by TEM and when a β-sheet CD signal predominates. vAβ1-42 shows negligible intensity at 
483 nm. Together these biophysical data suggest that vAβ1-42 does not self-assemble into amyloid while wild-type 
Aβ1-42 forms small oligomeric species followed by β-sheet rich amyloid fibres.
Solution state NMR has been used to monitor the change in solubility of Aβ peptides over time30, since the 
signal arising from the soluble peptide disappears as the peptide assembles beyond a certain size. Here, we exam-
ined the 1H NMR spectra from vAβ1-42 over three days and confirmed that the NMR signal remained strong 
and identical to time zero indicating that the peptide does not change structure or self-assemble during this time 
(Supplementary Figure 1).
vAβ1-42 does not form oligomers. Although the data outlined above indicate that vAβ1-42 is not assem-
bling into species that may contain β-sheet structure, it is possible that it is able to assemble into very small 
oligomers of a size below the resolution of TEM, and that do not exhibit β-sheet conformation or bind ThT. 
To explore this further, we used a series of antibodies directed against different conformations and epitopes to 
determine whether vAβ1-42 was forming any assemblies resembling those formed by Aβ1-42. Antibodies that 
bind to Aβ oligomers (NU1)31 or raised against the N or C-terminus (6E10 and 4G8 respectively) of Aβ were 
used for dot blotting (Fig. 2d). Aβ1-42 and vAβ1-42 were prepared at the same time points as in Fig. 2a–c. The 
oligomer-specific antibody (NU1) detected only Aβ1-42 indicating that vAβ1-42 does not form antibody detect-
able oligomers. The N-terminal antibody, 4G8, does not bind to vAβ1-42 as expected since the epitope overlaps 
with the F19S substitution. In contrast 6E10 binds to both peptides, confirming that vAβ1-42 can be detected by 
dot blotting. Notably there is a decrease in signal for each antibody with Aβ1-42 incubation time. This is consist-
ent with changes in conformation that accompany assembly to form fibrils which would reduce available epitopes. 
In contrast, there is no change in 6E10 intensity for vAβ1-42 over time consistent with the peptide remaining 
monomeric for up to 7 days.
Although dot blotting provides a useful way of looking at the antigenicity of Aβ1-42 and vAβ, due to the 
dynamic nature of amyloid assembly, the samples applied to the membrane probably contain a heterogeneous 
mixture of different species. To detect any assembled structures, we ran SDS-PAGE using samples collected at 
different incubation time points and then carried out a western blot with 6E10 (Fig. 2e). At the start of the experi-
ment Aβ1-42 is predominantly in a monomeric conformation (M) and migrates at around 4.5 kDa, with a signifi-
cant population of dimers (D, ~9 kDa) and trimers (T, ~13.5 kDa) present. After 2 hours, higher molecular weight 
oligomers form. These species migrate as a smear and, at later time points, the lower molecular weight monomer 
and oligomers disappear. After 7 days there are no oligomeric species present at all and fibrils are observed in 
the well of the gel. vAβ1-42 remains monomeric and migrates at 4.5 kDa for each incubation time point in the 
experiment (Fig. 2e).
vAβ1-42 is not toxic to primary hippocampal neurons and has no effect on metabolic activity in a 
human neuroblastoma cell line. Having established that in contrast to Aβ1-42, vAβ1-42 does not assemble 
into oligomers or fibrils, we sought to determine if there was a corresponding difference in function. There 
are numerous reports suggesting that pre-fibrillar, oligomeric species are the cause of the neurodegeneration 
observed in AD and toxicity in cell culture7,8. The preceding data reveals that Aβ1-42 is mostly oligomeric (i.e. not 
fibrillar, lacking in β-sheet structure and identifiable by anti-oligomer antibodies) at 2 to 4 hours post preparation. 
Therefore, for the remaining experiments, the peptide preparations were used at this time point. In addition, we 
chose to carry out these experiments out at a final peptide concentration of 10 μM, to ensure that any negative 
results were not due to low levels of peptide and accelerate the peptide effects within a reasonable time-frame.
Aβ1-42 oligomers have been shown to be toxic to cultured neuroblastoma cells and neurons27,32. In order to 
investigate this effect of Aβ1-42 on cells and compare to vAβ1-42, we conducted cell viability assays on two differ-
ent cell types, shown in Fig. 3. First, a live/dead cell assay was carried out using primary rat hippocampal neurons 
(Fig. 3a,b) and second the widely-used 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
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assay and CellTiter-Blue (CTB) assays were performed on human SH-SY5Y neuroblastoma cells (Fig. 3c,d) pro-
viding two independent verifications of metabolic activity and cell viability.
Figure 2. (a) Negative stain transmission electron microscopy images of Aβ1-42 (left panels) and vAβ1-42 
peptide (right panels) showing assembly of Aβ1-42 into fibrils at around 24 hours, preceded by small spherical 
structures (both shown by arrows). Conversely the vAβ1-42 peptide does not form fibres even up to 7 days. All 
peptides were prepared as described in the methods at 50 μM. Scale bars 200 nm. (b) CD spectra of Aβ1-42 and 
vAβ1-42 over time showing the formation of β-sheet structures for Aβ1-42 after around 24 hours whilst vAβ1-
42 remains as random coil structure up to the final time point of 7 days. (c) Thioflavin T fluorescence showing 
increasing fluorescence at 483 nm of Aβ1-42 over 7 days, compared to no change in fluorescence of vAβ1-42. 
(d) Sequence of Aβ1-42 (top) and vAβ1-42 (bottom), showing epitope regions for 4G8 and 6E10 antibodies. The 
amino acid substitutions are underlined. Dot blots using anti-oligomer antibody, NU1 and anti-Aβ antibodies 
4G8 and 6E10 show oligomer reactive species only in Aβ1-42 samples and not vAβ1-42. Similarly, 4G8 does not 
detect vAβ1-42 due to the F19S substitution in the epitope region. 6E10 binds both Aβ1-42 and vAβ1-42 as the 
epitope is the same in both peptides. (e) Western blot of Aβ1-42 (top) and vAβ1-42 (bottom) with 6E10 over 
time shows monomers (M), dimers (D), trimers (T), higher molecular weight species and fibres (F) are only 
formed by the wild-type peptide. vAβ1-42 runs as a monomer.
www.nature.com/scientificreports/
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The results revealed that oligomeric Aβ1-42 causes death of neurons while vAβ1-42 has no observable effects 
on cell health in any of the assays performed, even at high peptide concentrations. Primary neurons in culture are 
visibly affected with only a small population of healthy cells present at 3 days (Fig. 3a) and very few observable 
healthy cells after 7 days. In contrast, neurons treated with vAβ1-42 remain healthy over the time of the experi-
ment (Fig. 3b). The MTT (Fig. 3c) and CTB (Fig. 3d) assays show a decrease in the metabolic activity and viabilty 
of neuroblastoma cells treated with Aβ1-42. vAβ1-42 has no effect on cell viability in any of the assays conducted 
and is comparable to vehicle buffer only.
vAβ1-42 does not associate with primary hippocampal neurons. To provide additional insights into 
the behaviour of vAβ1-42 compared to Aβ1-42, we added each peptide (incubated for 2-4 hours) to primary rat 
hippocampal neurons and examined their distribution by two methods, immunolabelling with NU1 and 6E10 
and using fluorescently tagged peptides (Fig. 4). The antibody labeling to Aβ1-42 is detected in the cell body and 
along the axons (Fig. 4a,b, top panels) and persisted for at least 3 days. In contrast, neurons treated with vAβ1-42 
resemble the buffer only control (not shown) and show no labeling (bottom panels). Dot-blotting confirmed that 
6E10 is able to bind to vAβ1-42 (Fig. 2d,e). Therefore, these results indicate that vAβ1-42 neither able to bind to 
the cell membrane nor be internalised and is removed from the cells after washing. To confirm that vAβ1-42 did 
not associate with the cells rather than being simply undetectable, a variation of this experiment was conducted 
using Alexa Fluor tagged versions of the Aβ peptides. This method has been used by our group previously and the 
Figure 3. (a) DIC widefield images of neurons live in culture following treatment with either Aβ1-42 oligomers 
or vAβ1-42 after 3 or 7 days. Some live neurons are still clearly visible in the Aβ1-42 culture after 3 days but by 
7 days none appear healthy. Scale bar 20 μm. (b) Measurement of proportion of dead cells compared to the total 
counted in culture by Readyprobes assay following 3 and 7 days exposure to Aβ1-42 or vAβ1-42 or buffer only 
(total number of cells counted (number of dead cells in brackets) at 3 days: n = 1163 (545), 1012 (220) and 1661 
(279) and 7 days: n = 1032 (610), 684 (37) and 1112 (97) for Aβ1-42, vAβ1-42 and buffer respectively). (c) MTT 
assay (24 hours: n = 19, 9 and 20, 48 hours: n = 14, 9 and 13 for Aβ1-42, vAβ1-42 and buffer respectively) and (d) 
CTB (24 hours: n = 12, 11, and 16, 48 hours: n = 12, 9, and 18 for Aβ1-42, vAβ1-42 and buffer respectively) assay 
using SH-SY5Y cells. 10 μM oligomeric Aβ1-42 has a significant effect on the cells after 24 hours whilst vAβ1-42 
is the same as buffer only. Unpaired parametric student’s t test, only significant differences are shown, where 
p = < 0.05 (*), <0.01 (**), <0.0001 (****) and >0.05 was not significant. Error bars are expressed as ±SEM.
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fluorescent tag was shown not to affect assembly27. Cells treated with labeled versions of either Aβ1-42 or vAβ1-42 
looked similar to those treated with antibodies, with only fluorescent Aβ1-42 present along neurites and around 
the cell body and no fluorescent signal for the vAβ1-42 treated neurons, even after three days. Whether antibodies 
were used or not, there was no evidence that vAβ1-42 either bound to the outside of the cell nor was internalised.
vAβ1-42 has no effect on hippocampal synaptic function in primary hippocampal neurons. The 
function of small central synapses critically relies on the efficient fusion and retrieval of synaptic vesicles (SV). 
Aβ1-42 oligomers previously have been reported to modulate aspects of both recycling and vesicle pool organ-
isation33. Here we used FM1-43, a widely employed fluorescent reporter of vesicle turnover to investigate the 
effects of Aβ1-42 and vAβ1-42 on vesicle recycling parameters34. In double-blind experiments, primary hip-
pocampal neurons were treated 24 hours prior to imaging with a low concentration of 1 μM Aβ1-42, vAβ1-42, or 
buffer alone, and then subjected to field stimulation (1200 APs 20 Hz) in the presence of FM-dye to drive vesicle 
labelling (Fig. 5a). As a measure of synaptic vesicle recycling for the different treatments, representative images 
were collected after washing (Fig. 5b) and labelled terminals were quantified using a thresholding method (see 
Methods). Our analysis revealed that while vAβ1-42 and buffer alone had highly comparable synapse counts, the 
number of puncta in Aβ1-42-treated neurons was significantly lower (Fig. 5c, see figure legend for quantifica-
tion). These results reveal that Aβ1-42 treatment leads to a significant deficiency in the recruitment of functional 
synapses compared to vAβ1-42 peptide or buffer alone conditions. Next, the consequences of the three incuba-
tion treatments on activity-driven FM1-43 dye-loss from labelled terminals (a measure of vesicle release) were 
examined (Fig. 5d). The level of dye-loss was highly comparable for vAβ1-42 and buffer alone conditions but was 
significantly less in Aβ1-42 treated neurons suggesting an impairment in exocytosis (Fig. 5e,f). Taken together, 
these findings indicate specific deficits in vesicle recycling properties in Aβ1-42 treated synapses, which are not 
observed in vAβ1-42 or buffer control treatments.
Behavioural studies on an animal model (Lymnaea stagnalis, pond snail). To investigate possible 
effects of vAβ1-42 on whole animal function, we took advantage of a well-characterised model system, the pond 
snail, Lymnaea stagnalis. This system has been used extensively for studies of both behavior and learning and 
memory, due to its ability to undergo robust classical conditioning and form stable long-term memories (for 
review, see ref. 18). Recent work has demonstrated that Aβ1-42 significantly impairs recall of long-term memory 
associated with single-trial food-reward classical conditioning11. Here, to investigate whether vAβ1-42 showed 
the same effect, vAβ1-42 was administered to snails. Briefly, animals were conditioned to associate a chemical 
stimulus with a food stimulus (Fig. 6a). Consolidated long-term memory can be tested by administering the 
chemical stimulus then measuring the animals’ feeding response35. For this experiment, animals were trained 
at 0 hours, injected with peptide or controls at 24 hours, and tested at 48 hours to determine if vAβ1-42 disrupts 
consolidated long-term memory (Fig. 6a). Comparison of the peptide effect on the conditioned feeding response 
following incubation with Aβ1-42 or vAβ1-42 with the vehicle (buffer only) control is shown in Fig. 6b. While 
Aβ1-42 treated animals display decreased conditioned feeding response to the chemical stimulus in comparison 
to vehicle treated animals, vAβ1-42 treated animals exhibit a similar conditioned feeding response to the vehicle 
control, suggesting vAβ1-42 does not disrupt recall of consolidated long-term memory. These findings support 
our cellular-level results and suggest that vAβ1-42 is largely inconsequential for neural network function.
Our results reveal a striking and important contrast between the activity of wild-type Aβ1-42 peptide and 
the novel variant vAβ1-42. Here we show that only the wild-type assembles to form A11 positive oligomers and 
Figure 4. Hippocampal neurons treated with untagged oligomeric Aβ1-42 or vAβ1-42 (a,b) or Alexa fluor 
555 tagged peptides (c) and imaged by confocal microscopy. Cells in a and b were fixed and stained with anti-
oligomer antibody NU131 (a) or 6E10 (b). Maximum projection images of six 0.5 μm slices are shown in a and c, 
b shows one 1 μm slice from the centre of a Z-stack. Scale bars 20 μm.
www.nature.com/scientificreports/
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Figure 5. (a) Cartoon illustrating functional synaptic readout. Neurons are activated by field stimulation to 
evoke vesicle turnover in the presence of extracellular FM1-43-dye. Washing in dye-free solution leaves recently 
recycled vesicles fluorescently labelled. (b) Representative images of FM1-43 loading in neurons treated with 
Aβ1-42, vAβ1-42 or buffer. Arrowheads indicate discrete functional terminals. Scale bar 20 μm. (c) Histogram 
(median ± IQR) shows number of functional synapses expressed as the median synapse density per image, 
(Aβ1-42: 218 IQR 137-262, vAβ1-42: 315 IQR 258-355, buffer: 355 IQR 283–410, n = 20, 30, 30 images, 
respectively; Kruskal-Wallis one-way ANOVA, p = 0.0002 with Dunn’s multiple comparison test, see Methods 
for analysis). (d) Cartoon illustrating approach for readout of activity-induced dye-loss kinetics, corresponding 
to synaptic vesicle exocytosis. (e) Normalised fluorescence loss profiles for Aβ1-42, vAβ1-42 or buffer treated 
cells (average profiles of n = 218, 428, 560 synapses for Aβ1-42, vAβ1-42, buffer respectively). Shaded band 
denotes SEM for each trace. (f) Histogram of magnitude of FM1-43 destaining for data in (e), expressed as % 
dye loss (median ± IQR, Aβ1-42: 50 IQR 36-61, vAβ1-42: 71 IQR 56-82, buffer: 72 IQR 60-83, n = 218, 428, 560 
synapses, respectively; Kruskal-Wallis one-way ANOVA, p < 0.0001 with Dunn’s multiple comparison test).
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amyloid fibrils. The Aβ1-42 oligomers are able to bind to and internalise into neuronal cells and show accom-
panying cellular toxicity. In stark contrast, the non-assembling vAβ1-42 is not associated with cell membranes, 
internalised and nor does it affect neuronal survival. We show that Aβ1-42 oligomers can impair synaptic vesicle 
recruitment and exocytosis at synapses. Finally, we were able to utilize the peptide in an animal behavior assay 
and reveal that whilst Aβ1-42 impairs memory recall, vAβ1-42 has no such effect. Only by comparison with this 
rationally-designed peptide variant can robust conclusions can be drawn and exciting new insights made into the 
effects of Aβ on neuronal cell function and animal behavior.
Conclusions
Aβ is known to play an important role in the pathology of Alzheimer’s disease (AD), but the link between Aβ 
self-assembly and neurodegeneration remains elusive. It is clear however that the conformational change that 
accompanies assembly is a critical factor underlying amyloidogenic protein toxic action. To investigate this fur-
ther, we rationally designed a non-assembling peptide variant of Aβ1-42 that shares size and sequence with Aβ 
but does not self-assemble into oligomers or fibres. The identification of such a peptide is an essential contribution 
to the field and provides a powerful tool for elucidating structure-toxicity relationships and rigorously assessing 
the mechanisms of Aβ induced neuronal dysfunction in cellular assays and animal models.
Here, we have examined the potential amyloidogenic regions of Aβ1-42 and rationally designed a peptide 
variant that does not aggregate over the course of one week, does not cause toxicity in cell culture or behavioural 
effects in an animal model, nor binds to or is taken up by neuronal cells in culture. The double substitutions, 
F19S and G37D completely removed amyloidogenicity and the variant peptide was confirmed experimentally as 
assembly-incompetent. Several proof-of principle examples of the rational design strategy are provided, and show 
that self-assembly is key to Aβ1-42 detrimental effects.
Modelling the neurotoxic properties of Aβ1-42 using cells in culture is challenging but critical if its pathogenic 
mechanisms are to be understood at a molecular level. In AD, it is likely that a range of Aβ1-42 aggregates are 
produced that may all contribute to neuronal death and it may not be the case that one species in particular (e.g. 
dimer, trimer, octomer) is responsible. We sought to replicate this environment as closely as possible, carrying out 
our functional assays with a heterogeneous Aβ1-42 oligomer preparation in order to simulate how the dynamic 
nature of amyloid assembly, as well as the assemblies themselves, might be detrimental to cells. To this end, a 
suitable peptide that is unable to self-assemble is essential since it is not possible to produce a stable monomer of 
wild-type Aβ1-42.
Figure 6. (a) Cartoon illustrating conditioned feeding response of Lymnaea stagnalis treated with Aβ1-42 
or vAβ1-42. Animals were classically conditioned using the single-trial food-reward paradigm at 0 hours; 
injected with 1 μM Aβ1-42 (n = 55), 1 μM vAβ1-42 (n = 20), or vehicle (n = 106) at 24 hours; and tested for the 
conditioned feeding response at 48 hours. Picture inserts show an example of a complete feeding cycle (rasp) on 
which the behavioural assessment was based; rasping begins at 0 s, including opening of the mouth, protrusion 
of the toothed radula, ingestion of food, and closure of the mouth at 4 s. (b) One-way ANOVA, p < 0.0001. 
Tukey’s multiple comparison with p = 0.05: vAβ1-42 vs. Aβ1-42, Vehicle vs. Aβ1-42. Error bars are shown as 
±SEM.
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It is paramount that peptides, and not just buffers or vehicle solutions, are used to compare with wild-type Aβ 
in AD research. In our experiments, vAβ1-42 has the same effect as buffer controls, supporting observations that 
aggregated, and not monomeric isoforms of Aβ1-42 are toxic. These conclusions can only be drawn by comparison 
of Aβ1-42 with another peptide similar in sequence and, crucially, that has undergone the same preparation 
method. Solvents such as HFIP are often used to solubilise the peptide and can produce false positive results if 
not completely removed. By preparing vAβ1-42 using the procedure described here, any contaminating effects 
would be uncovered.
Our data show that vAβ1-42 remains in a soluble random coil conformation throughout the course of the 
experiment and it is likely that for this reason its detrimental effects are abrogated. The structure of Aβ1-42 oli-
gomers has been shown to play a very important role in their toxic function5,6,8,32 and these results confirm that 
oligomerisation is required for Aβ1-42 to associate with neurons, affect neuronal viability and exert behavioural 
effects.
The data described here outlines an unprecedented characterisation of a novel peptide and show unambig-
uously in several models that self-assembly is required for neurotoxicity. This novel peptide allows new insight 
into the pathway of Aβ action, revealing that β-sheet rich, oligomeric Aβ1-42 accumulates within neuronal cells. 
Our results show that it is likely that the oligomeric structure is crucial for membrane binding and internalisation. 
Once inside, it is able to exert detrimental effects on synaptic function in hippocampal neurons and on long-term 
memory in a model organism. In contrast, the non-assembling vAβ1-42 lacks the ability to form β-sheet rich 
oligomers and is unable to exert any of these effects, providing strong evidence that self-assembly is fundamental 
for the damaging effects of Aβ.
Materials and Methods
Peptide design. Sequence based design was performed using the WALTZ algorithm19 to explore the effect 
of amino-acid substitutions on the predicted amyloidogenicity of the Aβ1-42 peptide. The graph produced using 
WALTZ shows two peaks that indicate the location of two amyloidogenic regions (residues 16–21 and residues 
37–42) in the wildtype Aβ1-42 peptide. Substitutions were introduced within the predicted amyloidogenic 
regions to examine the effect on the graphical output prediction. All possible substitutions at positions 19 and 37 
were investigated and ranked based on their ability to reduce the amyloidogenicity peak. A number of variants 
were shown to reduce the predicted amyloidogenicity and two were selected based on previous experimental 
assembly studies.
Preparation of peptides. Hexafluoroisopropanol (HFIP) films of recombinant Aβ1-42 were purchased 
from rPeptide and vAβ1-42 was purchased from JPT. Peptides were prepared using an adapted protocol orig-
inally developed in17. HEPES buffer (10 mM HEPES, 50 mM NaCl, 1.6 mM KCl, 2 mM MgCl2, 3.5 mM CaCl2) 
was used to mimic the culture media as previously described3,17,27. All preparation was conducted using protein 
LoBind Eppendorfs and tips (Alpha Laboratories). Briefly, 0.2 mg Aβ1-42 (rPeptide) was solubilised in 200 μL 
HFIP (Sigma-Aldrich) to disaggregate the peptide. The solution was then vortexed on high for one minute and 
sonicated in a 50/60 Hz bath sonicator for five minutes. HFIP was dried completely using a low stream of nitrogen 
gas. Once completely dried, 200 μL dry dimethylsulfoxide (DMSO) (Sigma-Aldrich) was added, vortexed for 
one minute, and sonicated for one minute. Solutions were added to a 7K MWCO Zeba buffer-exchange column 
(Thermo Scientific) equilibrated with HEPES buffer with 40 μL HEPES as a stacking buffer. The protein solution 
was kept on ice and the absorbance at 280 nm measured with a NanoDrop spectrophotometer using a molar 
absorption coefficient of 1490 M−1 cm−1. Solutions were immediately diluted to 50 μM with HEPES buffer and 
incubated where indicated or used immediately in further experiments.
Generation of Alexa Fluor 555-conjugated peptides. Peptides were treated as outlined above up to 
the addition of 200 μl dry DMSO. The Alexa Fluor 555 tag was prepared as per manufacturers instructions (Life 
Technologies). Briefly, 10 μl H2O was added to the Alexa Fluor TFP ester and kept on ice. This was added to the 
peptide in 200 μl DMSO along with 10 μl 1 M sodium bicarbonate pH 8.3, mixed and incubated for 15 minutes at 
room temperature protected from light. Following this the procedure resumed as above and the solution added 
to the Zeba buffer exchange column. The calculations for the concentration was adjusted to take into account the 
absorbance of the dye.
Transmission electron microscopy. 4 μl of 50 μM Aβ was placed on the surface of Formvar/carbon film 
coated, 400 mesh copper grids (Agar Scientific) and allowed to absorb for two minutes and blotted dry. A 4 μl 
aliquot of milliQ-filtered water was then added to the grid and blotted. Immediately after this the grid was neg-
atively stained with 4 μl of 2% (w/v) uranyl acetate for 2 minutes, blotted and dried. The uranyl acetate wash was 
repeated once more and the grid was left to air dry. All TEM grids were examined using a Hitachi-7100 TEM 
at 100 kV and the images were acquired digitally with an axially mounted (2000 × 2000 pixel) Gatan Ultrascan 
1000 CCD camera. Aliquots of Aβ peptide samples were taken at different time points to monitor the fibrillation 
state and morphology.
Circular dichroism. 300 μl of 50 μM of Aβ peptide (prepared as described above) in phosphate buffer (pH7.4) 
was placed into a 1 mm path length quartz cuvette (Hellma) and scanned between 180 nm and 275 nm on a 
JASCO J715 Spectropolarimeter. The samples were equilibrated at 20 °C using a water bath. Three spectra were 
averaged for each measurement.
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Thioflavin T fluorescence. 10 μM of ThT in 50 μM Aβ peptide was added to a 10 mm cuvette. An emission 
scan between wavelength 460–600 nm was performed in a Varian Cary Eclipse Fluorescence Spectrophotometer. 
The sample compartment temperature was set to 21 °C, scan rate was 600 nm/min and three spectra were aver-
aged for each measurement.
Dot blotting. 5 μl of 50 μM Aβ peptide was spotted onto a nitrocellulose membrane and allowed to dry. The 
membrane was boiled with PBS for three minutes twice and then incubated at room temperature with blocking 
buffer (10% milk in 0.1% TBS-T) for 1 hour. The blocking buffer was poured off the membrane and replaced with 
primary antibody overnight at 4 °C. The membrane was washed for 10 minutes three times with 1% TBS-T before 
being incubated with HRP conjugated secondary antibody for 30 minutes. Following more washes the membrane 
was incubated with ECL substrate (Millipore) for three minutes before being developed. Antibodies were pur-
chased from Cambridge Bioscience (6E10 and 4G8). NU1 was a gift from the William Klein lab31.
Western Blotting. 2 μg of peptide in 4x Laemelli Sample Buffer (Bio-Rad) were loaded on a 4–20% 
Mini-PROTEAN TGX Stain-Free gel (Bio-Rad) and run in 1X running buffer (diluted from 10X stock of 25 mM 
Tris Base, 192 mM Glycine, 1% SDS) at 100V. The gel was then transferred in 1X transfer buffer (10% 10X stock 
(25 mM Tris Base, 192 mM Glycine), 10% Methanol, 80% ddH20) at 25V for 2 hours on to nitrocellulose 0.45 μm 
membrane. The membrane was blocked with 10% Milk/TBS-T at room temperature for 1 hour then incubated 
with a 1:10000 dilution of 6E10 antibody overnight at 4 °C. The membrane was washed three times for ten min-
utes with 1% TBS-T before being incubated with a 1:10000 dilution of HRP conjugated anti-mouse secondary 
antibody at room temperature for 30 minutes. The membrane was washed again three time for ten minutes with 
1% TBS-T and incubated with ECL substrate for five minutes before being developed.
Nuclear magnetic resonance. vAβ1-42 was prepared at 200 μM concentration in 10% v/v D2O standard. 
1H NMR spectra (128 scans) were acquired every 30 minutes over a period of 66 hours. The temperature was reg-
ulated at 25 °C. The spectra were processed with 1.5 Hz line broadening prior to base line correction and Fourier 
transformation. The residual solvent signal around 4.8 ppm was cut for clarity.
Cell culture. SH-SY5Y cells were cultured as described previously27 in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% Foetal Calf Serum, 1% Penicillin-Streptomycin and 2 mM L-Glutamine. Cells 
were passed every 4–5 days at around 80% confluency and not used beyond passage 19.
Rats are housed within a specialised facility under Home office guidelines and sacrificed using procedures 
in accordance with Animals (Scientific Procedures) Act 1986, Amendment Regulations 2012. Primary neurons 
were prepared from the hippocampus of P0-P1 rats by initially dissecting the tissue into ice cold HBSS containing 
0.1 M HEPES. Following washes in pre-warmed Basal Medium Eagle (BME) (Gibco) containing 0.5% glucose, 
2% FCS, 1 mM Na-Pyruvate, 0.01 M HEPES pH 7.35, 1% Penicillin-Streptomycin, 1% B27 supplement and 1% 
Glutamax, tissues were triturated using a 1 ml pipette until fully dissociated. The cell suspension was diluted 
further with complete BME media and approximately 40,000 cells plated into 2 cm2 wells containing a coverslip 
coated in 20 μg/ml Poly-D-Lysine with a layer of hippocampal astrocytes that had been growing for 4–5 days. 
After 2–3 days cells were treated with 3.25 μM cytosine arabinoside to curb further proliferation of astrocytes. 
Cells were used 10–14 days after plating.
Cell viability assay with primary hippocampal neurons. After the desired incubation time, one drop 
of each Readyprobes reagent (Life Technologies) was added per well. The kit contains a blue stain to label all cells, 
and a green stain to label dead cells only. Cells were incubated for 15 minutes then imaged on a Zeiss CO widefield 
microscope using DAPI and FITC filters. Images were analysed using FIJI software as follows. Regions of interest 
were drawn around neuronal cell bodies (astrocytes were excluded) using DIC and DAPI channels, which indi-
cated total cell number (live and dead). Background values in the green channel (dead cells) were determined and 
any value greater than this was ascribed as positive i.e. dead. Numbers of dead cells are expressed as a percentage 
of the total number of cells. Between nine and seventeen regions in total per sample were imaged from either 
two or three coverslips from experiments performed on three separate occasions using newly prepared peptide.
Cell metabolism assays with neuroblastoma cells. The Vybrant MTT [3-(4,5-dimethylthiazol-2-yl)-2, 
5-diphenyl-2H-tetrazolium bromide] cell-proliferation assay (Invitrogen) was used on undifferentiated SH-SY5Y 
cells according to the manufacturer’s protocol. Briefly, SH-SY5Y cells (10−4 cells/well) were seeded on a 96-well 
plate 2 days prior to the assay. The cells were then incubated with 10 μM oligomeric Aβ1-42 or vAβ1-42 for 24 
or 48 hours at 37 °C. At these time points, 12 mM MTT solution was added to the cells and further incubated for 
4 hours at 37 °C. The resulting insoluble dye was dissolved with 50 μL of DMSO and the absorbance measured at 
540 nm with a 620 nm reference filter. For CTB (Cell-Titer Blue), cells were plated as above except 2 hours before 
treatment with peptide, the media was replaced with serum-free media. After 24 or 48 hours, 20 μL of CTB dye 
was added to each well and further incubated for 6 hours. Fluorescence was measured at 570 nm. Experiments 
were carried out in triplicate a minimum of three times and the data pooled. Background absorbance or fluores-
cence was calculated from a dead cell control. Triplicate values were averaged then subtracted from sample values. 
This was carried out separately for each time point in each experiment. Statistical analysis was carried out using 
GraphPad Prism software.
Immunofluorescent labeling and confocal microscopy. Primary neuronal cells were treated with 1 μM 
of either Aβ1-42 or vAβ1-42 oligomers, or volume-matched buffer, for 24 and 72 hours. For 6E10 staining, 1 μM 
Aβ1-42 or 5 μM vAβ1-42 were added. After removal of media, cells were immediately fixed with 2% paraformal-
dehyde for 15 minutes. Following a wash with wash buffer (25% Superblock (Thermo Fisher) in PBS), cells were 
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permeabilised with 0.3% Triton-X 100 for 10 minutes then 50 mM glycine added to block unreacted aldehydes. 
Cells were incubated with Image-IT signal enhancer (Life Technologies) for 30 minutes then cells were blocked 
using undiluted Superblock for 30 minutes. Primary antibody NU131 or 6E10 (Cambridge Biosciences) (both 
1:500) diluted in wash buffer was incubated with the cells for one hour. After washing, Alexa Fluor 555 (6E10) 
or 488 (NU1) conjugated goat anti-mouse secondary antibody (1:500) (Life Technologies) was added for the 
same period and after a final wash the coverslips were mounted in ProLong Gold (Life Technologies), cured for 
2 days then imaged. Cells were imaged using a 63 × 1.2 NA water objective (tagged peptide or NU1 antibody) or 
a 40 × 1.1 NA water objective (6E10 antibody) on a Leica SP8 confocal microscope. Emission from NU1 stained 
cells (488 secondary) was collected using a 488 nm excitation laser line between 495 and 540 nm on a PMT 
detector. Emission from Alexa Fluor-555 tagged peptide treated cells and 6E10 stained cells (555 secondary) was 
collected using a 561 nm laser line between 555 and 650 nm. Samples were imaged sequentially.
For cells treated with tagged peptides, the cells were fixed, washed and mounted as described above.
Assessments of synaptic function. 10 days in vitro primary hippocampal neurons grown on coverslips 
were incubated for 24 h with 1 μM Aβ 1-42, vAβ1-42 or buffer control. For imaging experiments, a neuronal 
culture was transferred into external bath solution (in mM: 37 NaCl, 5 KCl, 2.5 CaCl2, 1 MgCl2, 10 D-glucose, 
5 HEPES, 20 μM 6-cyano-7-nitroquinoxaline-2,3-dione and 50 μM d(–)-2-amino-5-phosphonovaleric acid) and 
field stimulation (1200 APs at 20 Hz) applied in the presence of FM1-43 (10 μM) dye to label synapses. After 
completion of endocytosis, residual surface fluorescence was removed by washing in dye-free saline. The experi-
menter was blind to the treatment protocol for each coverslip during both imaging and data analysis. All analysis 
was carried out on non-filtered, raw images in ImageJ. For the quantification of functional synapses ten regions 
were sampled for each coverslip and converted to maximum intensity projections based on 4 × 0.5 µm image 
stacks. Terminals were identified using objective automated methods based on isodata thresholding (IJ_IsoData 
core function, ImageJ, NIH, USA). For activity-evoked dye-loss analysis, we applied a further destaining protocol 
(1200 APs 20 Hz) to FM1-43 dye-loaded coverslips while imaging. Destaining synapses were identified blindly on 
the basis of subtracted images before and after the destaining stimulus, and ROIs of equal size (2.1 × 2.1 µm) were 
drawn around fluorescent puncta. Background fluorescence was subtracted from each ROI and the destaining 
curves were normalised to the average value of five points before the onset of the stimulation. The % destaining 
was calculated using the average of the last five frames from the end of the stimulation. Images were collected on 
an Olympus BX61WI microscope equipped with a x60 1.0 N.A. dipping objective, excitation and emission filter 
sets at 480/20 and 520/35, and an Olympus XM10 camera with 2 × 2 binning. Statistical analysis was carried out 
in GraphPad Prism using Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple comparison test.
Comparison of the effect of the peptides on memory in Lymnaea stagnalis. Pond snails, Lymnaea 
stagnalis, were bred at the University of Sussex and maintained in large holding tanks containing 18–22 °C 
copper-free water, at a 12:12 hour light-dark cycle. The animals were fed Tetra-Phyll (TETRA Werke) twice a 
week and lettuce three times a week.
The peptides were administered to the animals directly after preparation. Using a 1 mL syringe with 30 gauge 
precision glide needles (Becton Dickinson), 100 μL of the Aβ1-42 or vAβ1-42 was injected into the haemolymph 
(~1 μL in volume) of each snail. The estimated final concentration in the animal was 0.1 μM for Aβ1-42 and 
vAβ1-42. As there is no blood-brain barrier in Lymnaea36, the injected peptides have direct access to the animal’s 
central nervous system. For vehicle-injected control animals, 100 μL of normal saline was injected.
Using well-established methods37, four-to six-month-old snails were removed from their home tanks and 
starved in new tanks for two days at the same temperature and light dark cycle as the home tanks. After the 
starvation period, the animals underwent single-trial food-reward classical conditioning35 in which the condi-
tioned stimulus (CS) (amyl acetate: 0.004% final concentration) and the unconditioned stimulus (US) (sucrose: 
0.6% final concentration) were paired. Initially, each individual snail was left to acclimatise in a 14 cm diameter 
Petri dish with 90 mL of 18–22 °C copper-free water for ten minutes. After the acclimatisation period, 5 mL of 
amyl acetate was added to the dish and after thirty seconds, 5 mL of sucrose was added. The snails were then left 
in their Petri dishes for two minutes, and then removed to their starvation tanks. Both the vehicle-injected and 
Aβ-injected groups were trained.
All animals were tested with the CS. Each individual snail was left to acclimatise in a 14 cm-diameter Petri 
dish with 90 mL of 18–22 °C copper-free water for ten minutes. After the acclimatisation period, 5 mL of 18–22 °C 
copper-free water was added to the dish. Rasps, the animals’ feeding movements, were manually counted for two 
minutes to determine a baseline rasping rate (number of rasps per two minutes) for each individual. After two 
minutes, 5 mL amyl acetate was added to the dish. Rasping was tracked for two minutes. Rasping rates were deter-
mined by subtracting the individual animal’s baseline rasp from the amyl acetate induced rasp.
Data that passed the D’Agostino and Pearson omnibus normality test were subjected to parametric tests 
(one-way analysis of single variance [ANOVA] with Tukey’s multiple comparison) to establish significance (cri-
terion, p < 0.05). GraphPad Prism software was used for all analyses.
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